Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Eli Lilly’s Weight Loss Drug Zepbound Cuts Sleep Apnea Severity
Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based … [Read more...]
Incannex CEO: ‘Remarkable’ Results Drive Sleep Apnea Drug Trial
Summary: Incannex Health care Inc furnished an update on its stage 2/3 trials of IHL-42X, its drug candidate becoming formulated for the procedure of obstructive rest apnea (OSA), detailing preparation throughout 25 US web sites with growth plans into Europe. This proprietary … [Read more...]
Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate
Summary: Zevra Therapeutics Inc., in its yr-conclude fiscal and corporate update for 2023, highlighted the development of KP1077 in dealing with idiopathic hypersomnia, citing promising Stage 2 analyze final results. The organization also introduced designs to existing new info … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]
Anxiety Drug Pregabalin Linked to Rising Number of Deaths – Here’s What You Should Know
By Ian Hamilton, University of York and Harry Sumnall, Liverpool John Moores University There has been a significant rise in deaths linked to the commonly prescribed anxiety drug, pregabalin. While in 2018 there were 187 deaths linked to pregabalin in England and Wales, this … [Read more...]